Interleukin-1 receptorantagonistbehandling af patienter med type 2-diabetes--sekundaerpublikation.

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Interleukin-1 receptorantagonistbehandling af patienter med type 2-diabetes--sekundaerpublikation. / Larsen, Claus Morten; Faulenbach, Mirjam; Vaag, Allan; Vølund, Aage; Ehses, Jan; Seifert, Burkhardt; Mandrup-Poulsen, Thomas; Donath, Marc.

In: Ugeskrift for læger, Vol. 169, No. 45, 2007, p. 3868-71.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Larsen, CM, Faulenbach, M, Vaag, A, Vølund, A, Ehses, J, Seifert, B, Mandrup-Poulsen, T & Donath, M 2007, 'Interleukin-1 receptorantagonistbehandling af patienter med type 2-diabetes--sekundaerpublikation.', Ugeskrift for læger, vol. 169, no. 45, pp. 3868-71.

APA

Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J., Seifert, B., Mandrup-Poulsen, T., & Donath, M. (2007). Interleukin-1 receptorantagonistbehandling af patienter med type 2-diabetes--sekundaerpublikation. Ugeskrift for læger, 169(45), 3868-71.

Vancouver

Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses J, Seifert B et al. Interleukin-1 receptorantagonistbehandling af patienter med type 2-diabetes--sekundaerpublikation. Ugeskrift for læger. 2007;169(45):3868-71.

Author

Larsen, Claus Morten ; Faulenbach, Mirjam ; Vaag, Allan ; Vølund, Aage ; Ehses, Jan ; Seifert, Burkhardt ; Mandrup-Poulsen, Thomas ; Donath, Marc. / Interleukin-1 receptorantagonistbehandling af patienter med type 2-diabetes--sekundaerpublikation. In: Ugeskrift for læger. 2007 ; Vol. 169, No. 45. pp. 3868-71.

Bibtex

@article{e7035300acd111ddb538000ea68e967b,
title = "Interleukin-1 receptorantagonistbehandling af patienter med type 2-diabetes--sekundaerpublikation.",
abstract = "Interleukin-1 receptor antagonist (IL-1Ra) expression is reduced in islets of patients with type 2 diabetes. 70 patients with type 2 diabetes were randomized to treatment with anakinra (IL-1Ra) or placebo for 13 weeks. Following treatment glycated hemoglobin was 0.46 percent lower, C-peptide secretion was enhanced, and systemic IL-6 and C-reactive protein levels were reduced in the anakinra group compared to the placebo group. Insulin resistance remained unchanged. Blocking IL-1 activity improved glycemia and b-cell secretory function and reduced markers of systemic inflammation. Udgivelsesdato: 2007-Nov-5",
author = "Larsen, {Claus Morten} and Mirjam Faulenbach and Allan Vaag and Aage V{\o}lund and Jan Ehses and Burkhardt Seifert and Thomas Mandrup-Poulsen and Marc Donath",
year = "2007",
language = "Dansk",
volume = "169",
pages = "3868--71",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "45",

}

RIS

TY - JOUR

T1 - Interleukin-1 receptorantagonistbehandling af patienter med type 2-diabetes--sekundaerpublikation.

AU - Larsen, Claus Morten

AU - Faulenbach, Mirjam

AU - Vaag, Allan

AU - Vølund, Aage

AU - Ehses, Jan

AU - Seifert, Burkhardt

AU - Mandrup-Poulsen, Thomas

AU - Donath, Marc

PY - 2007

Y1 - 2007

N2 - Interleukin-1 receptor antagonist (IL-1Ra) expression is reduced in islets of patients with type 2 diabetes. 70 patients with type 2 diabetes were randomized to treatment with anakinra (IL-1Ra) or placebo for 13 weeks. Following treatment glycated hemoglobin was 0.46 percent lower, C-peptide secretion was enhanced, and systemic IL-6 and C-reactive protein levels were reduced in the anakinra group compared to the placebo group. Insulin resistance remained unchanged. Blocking IL-1 activity improved glycemia and b-cell secretory function and reduced markers of systemic inflammation. Udgivelsesdato: 2007-Nov-5

AB - Interleukin-1 receptor antagonist (IL-1Ra) expression is reduced in islets of patients with type 2 diabetes. 70 patients with type 2 diabetes were randomized to treatment with anakinra (IL-1Ra) or placebo for 13 weeks. Following treatment glycated hemoglobin was 0.46 percent lower, C-peptide secretion was enhanced, and systemic IL-6 and C-reactive protein levels were reduced in the anakinra group compared to the placebo group. Insulin resistance remained unchanged. Blocking IL-1 activity improved glycemia and b-cell secretory function and reduced markers of systemic inflammation. Udgivelsesdato: 2007-Nov-5

M3 - Tidsskriftartikel

C2 - 18031661

VL - 169

SP - 3868

EP - 3871

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 45

ER -

ID: 8465591